The Wegovy weight loss pill is now available in U.S.

Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering 1.5 milligram and 4 mg doses at $149 per month for self-paying patients in an intensely competitive weight-loss drug market

Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering 1.5 milligram and 4 mg doses at $149 per month for self-paying patients in an intensely competitive weight-loss drug market.

The pill was approved by the Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to U.S. rival Eli Lilly. Lilly has previously said it expects a decision in March.

Novo’s pill will also be sold in 9 mg and a higher long-term dose of 25 mg. The two higher doses will be priced at $299 for a month’s supply, while the 4 mg dose will rise to $199 from April 15, the drugmaker’s website shows.

The Wegovy pill could attract new consumers as Novo looks to revive its fortunes after profit warnings and sliding shares last year. The treatment offers more flexibility and an alternative for those who dislike needles used in injectable medication.

The once-daily pill is also under review by other regulators, with a UK decision due by year-end.